Andrea Corona MapLight reports mixed results in Schizophrenia trial In their Phase 2 ZEPHR trial, MapLights novel oral drug for schizophrenia, the Ml/M4 muscarinic agonist ML-007C-MA, successfully hit its primary endpoint but only for the twice-daily version, not the once-daily dose
Arumugam et al., 2011)
For those experiencing alopecia or thinning hair, the growth phase shortens, and more follicles enter the resting or shedding stage prematurely
Cagrilintide handles appetite suppression through the amylin pathway, while Semaglutide works through GLP-1 receptors
a precision-based, biomarker- and phenotype-driven approach offers the safest, most efficacious route forward
Here, those phrases are handled only as research-language examples, not product uses, outcomes, instructions, or recommendations